Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared on X:
“I wonder how you would treat a patient after nephro-uretectomy for a high grade, T3N0M0 upper tract urothelial cancer.
The tumor is PD-L1+ve and ctDNA-ve. The patient is not eligible for cisplatin.”
You can also read:
Atezolizumab Plus Gemcitabine/Cisplatin in Metastatic Urothelial Cancer
